Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.68 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 14/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389262 | 1.00 | TRPV1 (0.68) | TRPV1ENPP2MAPK1GPR139ALDH1A1 | |
| SCHEMBL307996 | 0.91 | TRPV1 (0.82) | TRPV1ENPP2MAPK1GPR139ALDH1A1 | |
| SCHEMBL308087 | 0.91 | TRPV1 (0.82) | TRPV1ENPP2MAPK1GPR139ALDH1A1 | |
| SCHEMBL307997 | 0.91 | TRPV1 (0.82) | TRPV1ENPP2MAPK1GPR139ALDH1A1 | |
| SCHEMBL308037 | 0.90 | TRPV1 (0.69) | TRPV1ENPP2MAPK1GPR139ALDH1A1 | |
| SCHEMBL308036 | 0.90 | TRPV1 (0.69) | TRPV1ENPP2MAPK1GPR139ALDH1A1 | |
| SCHEMBL14291910 | 0.90 | TRPV1 (0.71) | TRPV1ENPP2MAPK1GPR139ALDH1A1 | |
| SCHEMBL306518 | 0.88 | TRPV1 (0.58) | TRPV1ENPP2MAPK1GPR139ALDH1A1 | |
| SCHEMBL306519 | 0.88 | TRPV1 (0.58) | TRPV1ENPP2MAPK1GPR139ALDH1A1 | |
| SCHEMBL308183 | 0.88 | TRPV1 (0.54) | TRPV1ENPP2MAPK1GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | claimed |
| US-7906654-B2 | (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221188-A1 | New Benzimidazole Derivatives | OPRD1, OPRK1, SDHA | TRPV1 10/4885ENPP2 3316/4885MAPK1 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.